QQQ   306.17 (+2.59%)
AAPL   149.24 (+2.54%)
MSFT   266.82 (+2.03%)
FB   202.62 (+1.29%)
GOOGL   2,329.46 (+1.77%)
AMZN   2,307.37 (+4.11%)
TSLA   761.61 (+5.14%)
NVDA   181.77 (+5.29%)
BABA   91.99 (+6.37%)
NIO   16.63 (+14.30%)
AMD   102.47 (+8.73%)
CGC   5.89 (+2.79%)
MU   74.48 (+5.69%)
T   20.57 (+1.43%)
GE   76.40 (+2.37%)
F   13.53 (+3.68%)
DIS   108.64 (+3.29%)
AMC   12.90 (+10.16%)
PFE   51.34 (+1.32%)
PYPL   79.75 (+2.70%)
NFLX   190.56 (+2.17%)
QQQ   306.17 (+2.59%)
AAPL   149.24 (+2.54%)
MSFT   266.82 (+2.03%)
FB   202.62 (+1.29%)
GOOGL   2,329.46 (+1.77%)
AMZN   2,307.37 (+4.11%)
TSLA   761.61 (+5.14%)
NVDA   181.77 (+5.29%)
BABA   91.99 (+6.37%)
NIO   16.63 (+14.30%)
AMD   102.47 (+8.73%)
CGC   5.89 (+2.79%)
MU   74.48 (+5.69%)
T   20.57 (+1.43%)
GE   76.40 (+2.37%)
F   13.53 (+3.68%)
DIS   108.64 (+3.29%)
AMC   12.90 (+10.16%)
PFE   51.34 (+1.32%)
PYPL   79.75 (+2.70%)
NFLX   190.56 (+2.17%)
QQQ   306.17 (+2.59%)
AAPL   149.24 (+2.54%)
MSFT   266.82 (+2.03%)
FB   202.62 (+1.29%)
GOOGL   2,329.46 (+1.77%)
AMZN   2,307.37 (+4.11%)
TSLA   761.61 (+5.14%)
NVDA   181.77 (+5.29%)
BABA   91.99 (+6.37%)
NIO   16.63 (+14.30%)
AMD   102.47 (+8.73%)
CGC   5.89 (+2.79%)
MU   74.48 (+5.69%)
T   20.57 (+1.43%)
GE   76.40 (+2.37%)
F   13.53 (+3.68%)
DIS   108.64 (+3.29%)
AMC   12.90 (+10.16%)
PFE   51.34 (+1.32%)
PYPL   79.75 (+2.70%)
NFLX   190.56 (+2.17%)
QQQ   306.17 (+2.59%)
AAPL   149.24 (+2.54%)
MSFT   266.82 (+2.03%)
FB   202.62 (+1.29%)
GOOGL   2,329.46 (+1.77%)
AMZN   2,307.37 (+4.11%)
TSLA   761.61 (+5.14%)
NVDA   181.77 (+5.29%)
BABA   91.99 (+6.37%)
NIO   16.63 (+14.30%)
AMD   102.47 (+8.73%)
CGC   5.89 (+2.79%)
MU   74.48 (+5.69%)
T   20.57 (+1.43%)
GE   76.40 (+2.37%)
F   13.53 (+3.68%)
DIS   108.64 (+3.29%)
AMC   12.90 (+10.16%)
PFE   51.34 (+1.32%)
PYPL   79.75 (+2.70%)
NFLX   190.56 (+2.17%)
NASDAQ:CODX

Co-Diagnostics (CODX) Stock Forecast, Price & News

$5.03
+0.33 (+7.02%)
(As of 05/17/2022 04:00 PM ET)
Add
Compare
Today's Range
$4.68
$5.09
50-Day Range
$3.76
$6.56
52-Week Range
$3.66
$11.82
Volume
250,827 shs
Average Volume
430,550 shs
Market Capitalization
$170.96 million
P/E Ratio
3.87
Dividend Yield
N/A
Beta
-1.9
30 days | 90 days | 365 days | Advanced Chart
Receive CODX News and Ratings via Email

Sign-up to receive the latest news and ratings for Co-Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

Co-Diagnostics logo

About Co-Diagnostics

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CODX
Fax
N/A
Employees
101
Year Founded
N/A

Sales & Book Value

Annual Sales
$97.89 million
Cash Flow
$1.42 per share
Book Value
$4.65 per share

Profitability

Net Income
$36.66 million
Pretax Margin
48.58%

Debt

Price-To-Earnings

Miscellaneous

Free Float
33,648,000
Market Cap
$170.96 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/12/2022
Today
5/17/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.14 out of 5 stars

Medical Sector

433rd out of 1,426 stocks

Surgical & Medical Instruments Industry

52nd out of 138 stocks

Analyst Opinion: 3.3Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 3.1 5 -4 -3 -2 -1 -













Co-Diagnostics (NASDAQ:CODX) Frequently Asked Questions

Is Co-Diagnostics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Co-Diagnostics stock.
View analyst ratings for Co-Diagnostics
or view top-rated stocks.

Are investors shorting Co-Diagnostics?

Co-Diagnostics saw a drop in short interest in the month of April. As of April 30th, there was short interest totaling 1,430,000 shares, a drop of 29.9% from the April 15th total of 2,040,000 shares. Based on an average trading volume of 356,600 shares, the short-interest ratio is presently 4.0 days.
View Co-Diagnostics' Short Interest
.

When is Co-Diagnostics' next earnings date?

Co-Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Co-Diagnostics
.

How were Co-Diagnostics' earnings last quarter?

Co-Diagnostics, Inc. (NASDAQ:CODX) announced its earnings results on Thursday, May, 12th. The company reported $0.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.16. Co-Diagnostics had a trailing twelve-month return on equity of 32.20% and a net margin of 40.25%. During the same quarter in the previous year, the firm posted $0.26 earnings per share.
View Co-Diagnostics' earnings history
.

What guidance has Co-Diagnostics issued on next quarter's earnings?

Co-Diagnostics issued an update on its first quarter 2022 earnings guidance on Thursday, April, 21st. The company provided earnings per share guidance of $0.170-$0.200 for the period, compared to the consensus estimate of $0.110. The company issued revenue guidance of $21 million-$22 million, compared to the consensus revenue estimate of $21.28 million.

What price target have analysts set for CODX?

3 Wall Street analysts have issued 1 year price objectives for Co-Diagnostics' stock. Their forecasts range from $12.00 to $14.00. On average, they expect Co-Diagnostics' share price to reach $13.00 in the next year. This suggests a possible upside of 158.4% from the stock's current price.
View analysts' price targets for Co-Diagnostics
or view top-rated stocks among Wall Street analysts.

Who are Co-Diagnostics' key executives?
Co-Diagnostics' management team includes the following people:
  • Mr. Dwight H. Egan, Chairman, CEO & Pres (Age 69, Pay $1.02M)
  • Mr. Brian L. Brown CPA, CFO & Company Sec. (Age 46, Pay $730.62k)
  • Mr. Reed L. Benson, Gen. Counsel (Age 74, Pay $385.85k) (LinkedIn Profile)
  • Dr. Brent C. Satterfield Ph.D., Co-Founder & Member of Scientific Advisory Board (Age 45)
  • Dr. Jesse Montgomery, Chief Scientific Officer
  • Mr. Andrew Benson, Head of Investor Relations
  • Dr. Mayuranki Almaula, Sr. VP of Overseas Operations & Strategic Alliances
  • Mr. Cameron Gundry, Head of Commercialization LATAM/EUR
What other stocks do shareholders of Co-Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Co-Diagnostics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Moderna (MRNA), Vaxart (VXRT), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), iBio (IBIO), Advanced Micro Devices (AMD), Pfizer (PFE) and Johnson & Johnson (JNJ).

When did Co-Diagnostics IPO?

(CODX) raised $9 million in an initial public offering (IPO) on Thursday, July 13th 2017. The company issued 1,300,000 shares at $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities acted as the underwriters for the IPO.

What is Co-Diagnostics' stock symbol?

Co-Diagnostics trades on the NASDAQ under the ticker symbol "CODX."

Who are Co-Diagnostics' major shareholders?

Co-Diagnostics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.51%), Renaissance Technologies LLC (1.73%), BlackRock Inc. (1.44%), Advisor Resource Council (0.78%), Bank of New York Mellon Corp (0.67%) and Easterly Investment Partners LLC (0.42%). Company insiders that own Co-Diagnostics stock include Dwight H Egan, Eugene Durenard, Reed L Benson and Richard S Serbin.
View institutional ownership trends for Co-Diagnostics
.

Which institutional investors are selling Co-Diagnostics stock?

CODX stock was sold by a variety of institutional investors in the last quarter, including Group One Trading L.P., Charles Schwab Investment Management Inc., Advisor Resource Council, Principal Financial Group Inc., Advisor Group Holdings Inc., Easterly Investment Partners LLC, Walleye Trading LLC, and Simplex Trading LLC. Company insiders that have sold Co-Diagnostics company stock in the last year include Eugene Durenard, and Reed L Benson.
View insider buying and selling activity for Co-Diagnostics
or view top insider-selling stocks.

Which institutional investors are buying Co-Diagnostics stock?

CODX stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Vanguard Group Inc., Acadian Asset Management LLC, Engineers Gate Manager LP, Bank of New York Mellon Corp, State of Tennessee Treasury Department, Qube Research & Technologies Ltd, and Prelude Capital Management LLC.
View insider buying and selling activity for Co-Diagnostics
or or view top insider-buying stocks.

How do I buy shares of Co-Diagnostics?

Shares of CODX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Co-Diagnostics' stock price today?

One share of CODX stock can currently be purchased for approximately $5.03.

How much money does Co-Diagnostics make?

Co-Diagnostics has a market capitalization of $170.96 million and generates $97.89 million in revenue each year. The company earns $36.66 million in net income (profit) each year or $1.30 on an earnings per share basis.

How many employees does Co-Diagnostics have?

Co-Diagnostics employs 101 workers across the globe.

What is Co-Diagnostics' official website?

The official website for Co-Diagnostics is www.codiagnostics.com.

How can I contact Co-Diagnostics?

Co-Diagnostics' mailing address is 2401 SOUTH FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT, 84124. The company can be reached via phone at (801) 438-1036 or via email at [email protected].

This page was last updated on 5/17/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.